Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nova Eye Medical ( (AU:EYE) ) has provided an announcement.
Nova Eye Medical Limited has made significant strides in the glaucoma surgical devices market with its iTrack™ Advance, achieving a 26% increase in US sales and a record $29.3 million in revenue. The company is expanding globally, with regulatory approval in China and a strong presence in Germany, while enhancing production capabilities to meet growing demand.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
More about Nova Eye Medical
Nova Eye Medical Limited operates in the global glaucoma surgical devices market, focusing on innovative solutions for glaucoma, a leading cause of irreversible blindness. Their primary product, the iTrack™ Advance, is a minimally invasive microcatheter designed for keyhole eye surgery, offering effective pressure reduction and long-term benefits without leaving implants.
Average Trading Volume: 306,004
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$35.6M
See more data about EYE stock on TipRanks’ Stock Analysis page.